CurrentEndo
Get Weekly

CurrentEndo coverage · page 21 of 55

Diabetes, Obesity and Metabolism

Briefs 801–840 of 2,200 CurrentEndo has covered from this journal, newest publication first

Latest from Diabetes, Obesity and Metabolism

All coverage, newest first

  1. Diabetes Obes Metab

    Real‐world incidence and risk factors of level 3 (severe) hypoglycaemia in adults with type 1 or 2 diabetes ( iNPHORM , United States)

    Cohort studyComplications

  2. Diabetes Obes Metab

    Cardiorespiratory fitness and type 2 diabetes risk: A prospective cohort study with mediation analysis of biological aging in the UK Biobank

    Cohort studyT2D & other

  3. Diabetes Obes Metab

    Pharmacological intervention: Challenges and promising outcomes for fat loss and preservation of lean body mass in the treatment of overweight and type 2 diabetes

    Research articleT2D & other

  4. Diabetes Obes Metab

    Synergistic associations of metformin and GLP ‐1 receptor agonist use with adiposity‐related cancer incidence in people living with type 2 diabetes

    Cohort studyT2D & other

  5. Diabetes Obes Metab

    Progressive increases in adiposity and ectopic fat surrogates across glycaemic states highlight weight reduction as a key target for type 2 diabetes prevention, especially in younger people

    Cross-sectional studyT2D & other

  6. Diabetes Obes Metab

    Importance of targeting post‐prandial hyperglycaemia to achieve HbA1c goals in insulin glargine‐treated subphenotypes of type 2 diabetes

    Meta-analysisT2D & other

  7. Diabetes Obes Metab

    Improving cardiovascular risk stratification through the derivation and validation of an elevated triglyceride‐glucose index

    Cohort study

  8. Diabetes Obes Metab

    Continuous glucose monitoring in early gestational diabetes improves maternal and neonatal outcomes—The Steady Sugar trial

    Randomized controlled trialDiabetes in pregnancy

  9. Diabetes Obes Metab

    Adverse cardiometabolic profile of women 6 months and 2 years after gestational hypertension

    Secondary analysis

  10. Diabetes Obes Metab

    Availability and readiness of health facilities for chronic kidney disease, diabetes and cardiovascular disease in Ethiopia: Evidence from service provision assessment data

    Cross-sectional studyT2D & other

  11. Diabetes Obes Metab

    Evolving trends of antidiabetic agents stratified by age, kidney function and body mass index: Insights from a nationwide claims database

    Cohort studyT2D & other

  12. Diabetes Obes Metab

    Two‐tier screening approach for liver fibrosis stratification in outpatients with type 2 diabetes mellitus: A multicenter cross‐sectional study

    Cross-sectional studyT2D & other

  13. Diabetes Obes Metab

    Glucagon‐like peptide‐1 receptor agonist versus sodium‐glucose cotransporter‐2 inhibitor persistence in Medicare Advantage beneficiaries with type 2 diabetes, cardiovascular risk, and obesity

    Cohort studyT2D & other

  14. Diabetes Obes Metab

    Comparison of the renal outcomes of novel antidiabetic agents in patients with type 2 diabetes with chronic kidney disease: A systematic review and network meta‐analysis of randomized controlled trials

    Meta-analysisT2D & other

  15. Diabetes Obes Metab

    Blood pressure and adverse cardiovascular outcomes in older people with type 2 diabetes and chronic kidney disease: Findings based on the Clinical Practice Research Datalink databases in England

    Cohort studyT2D & other

  16. Diabetes Obes Metab

    Effectiveness and safety of GLP ‐1 receptor agonists in craniopharyngioma patients with obesity: A multicentre real‐world study

    Cohort studyPituitary

  17. Diabetes Obes Metab

    Changes to insulin requirements over time with semaglutide in adults with type 1 diabetes on insulin pump therapy: A post‐hoc analysis of a double‐blinded, randomised, crossover trial

    Secondary analysisTechnology

  18. Diabetes Obes Metab

    Control of the cardiovascular risk factors in patients with type 2 diabetes mellitus in China in 2023–2024

    Cohort studyT2D & other

  19. Diabetes Obes Metab

    Digital engagement enhances dual GIP / GLP ‐1 receptor agonist and GLP ‐1 receptor agonist efficacy: A retrospective cohort analysis of a digital weight loss service on outcomes and safety

    Cohort studyObesity

  20. Diabetes Obes Metab

    Genotype‐guided dual antiplatelet therapy in minor stroke or transient ischemic attack with metabolic syndrome: A post hoc analysis of CHANCE ‐2

    Secondary analysis

  21. Diabetes Obes Metab

    One‐year effectiveness and safety in young children aged 2–6 years with type 1 diabetes using an automated insulin delivery system: A real‐world prospective cohort study

    Cohort studyTechnology

  22. Diabetes Obes Metab

    Plasma proteomics identifies potential drug targets for diabetic polyneuropathy: Evidence from prospective cohorts and genetic analysis

    Mechanistic studyComplications

  23. Diabetes Obes Metab

    Weight‐reducing treatments are associated with an improvement in depression, functional health status, and quality of life: A meta‐analysis of randomized controlled trials

    Meta-analysisObesity

  24. Diabetes Obes Metab

    A double‐blind study on ulotaront's impact on weight‐related parameters in schizophrenia patients with metabolic syndrome and prediabetes: Part II

    Randomized controlled trialT2D & other

  25. Diabetes Obes Metab

    An open‐label study on ulotaront's effects on insulin‐glucose regulation in schizophrenia patients with metabolic syndrome and prediabetes: Part I

    Research articleT2D & other

  26. Diabetes Obes Metab

    Antidiabetic agents and dementia risk in type 2 diabetes: A systematic review and network meta‐analysis

    Meta-analysisT2D & other

  27. Diabetes Obes Metab

    Psychiatric effects of GLP ‐1 receptor agonists: A systematic review of emerging evidence

    Meta-analysisT2D & other

  28. Diabetes Obes Metab

    Baseline HbA1c and dementia risk at SGLT2i initiation in type 2 diabetes

    Cohort studyT2D & other

  29. Diabetes Obes Metab

    Efficacy and safety of European Medicines Agency ( EMA )‐approved pharmacological, endoscopic, and surgical treatments in different classes of obesity: A network meta‐analysis of randomised controlled trials for the development of the SIO (Società Italiana Obesità) Italian guidelines for the diagnosis and treatment of overweight and obesity

    Meta-analysisObesity

  30. Diabetes Obes Metab

    Glucagon‐like peptide‐1 receptor agonist treatment reduces body weight and improves glycaemic outcomes in patients with concurrent overweight/obesity and type 1 diabetes: A systematic review and meta‐analysis

    Meta-analysisT1D

  31. Diabetes Obes Metab

    Exploring the interaction between ethnicity, deprivation and the use of CGM on diabetes outcomes—A study from the Association of British Clinical Diabetologists

    Cohort studyTechnology

  32. Diabetes Obes Metab

    GLP ‐ 1RA and the risk of non‐arteritic anterior ischaemic optic neuropathy in patients with type 2 diabetes: A population‐based study

    Cohort studyT2D & other

  33. Diabetes Obes Metab

    Independent and joint association of fat‐to‐muscle mass ratio and cardiorespiratory fitness with type 2 diabetes mellitus incidence: A prospective cohort study

    Cohort studyT2D & other

  34. Diabetes Obes Metab

    Low serum 1,5‐anhydroglucitol is associated with increased risk of all‐cause and cardiovascular mortality in type 2 diabetes: A real‐world cohort study

    Cohort studyT2D & other

  35. Diabetes Obes Metab

    Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials

    Trial designObesity

  36. Diabetes Obes Metab

    Comparative healthcare resource utilization and costs of empagliflozin and GLP ‐1 receptor agonists in type 2 diabetes

    Cohort studyT2D & other

  37. Diabetes Obes Metab

    Triple oral therapy with metformin, DPP ‐4 inhibitor, and SGLT2 inhibitor for adults with type 2 diabetes: Consensus recommendations of a Chinese expert panel (version 2025)

    Guideline or statementT2D & other

  38. Diabetes Obes Metab

    Efficacy and safety of iGlarLixi versus IDegAsp by baseline β‐cell function in Chinese people with type 2 diabetes: Exploratory analyses of the Soli‐D study

    Secondary analysisT2D & other

  39. Diabetes Obes Metab

    Acute effects of GIP and GLP ‐1 receptor antagonism in totally pancreatectomized individuals: A randomized double‐blind, placebo‐controlled crossover study

    Randomized controlled trial

  40. Diabetes Obes Metab

    Partial non‐adherence to antidiabetic therapy undermines diabetes management and correlates with treatment complexity: A cross‐sectional study using blood plasma analysis

    Cross-sectional studyT2D & other

All 2,200 Briefs in ExploreShowing Briefs 801–840 of 2,200, newest first